Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Ira Colvard

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

A total of 3 analysts rate Collegium Pharmaceutical (NASDAQ:COLL) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:COLL) has 4 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Tuesday, January 23 the stock has “Buy” rating by Piper Jaffray. On Monday, June 11 the rating was initiated by Cantor Fitzgerald with “Buy”. On Sunday, February 11 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Jefferies. On Monday, February 12 the firm earned “Buy” rating by Piper Jaffray. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $40.0000 Initiate
12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain

COLL is reaching $25.65 during the last trading session, after decreased 0.58%.Currently Collegium Pharmaceutical, Inc. is uptrending after 169.07% change in last June 27, 2017. COLL has also 11,110 shares volume. The stock outperformed the S&P 500 by 156.50%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $847.58 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news brought out briefly go to: Benzinga.com, Schaeffersresearch.com, Nasdaq.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “Cantor Fitzgerald Out Bullish On Collegium As ‘Leading Company’ In Pain Management” brought out on June 12, 2018, “2 Healthcare Stocks Expected to Skyrocket” on June 12, 2018, “New Research: Key Drivers of Growth for Outfront Media, Enel Chile, Banc of California, Northern Dynasty Minerals …” with a publish date: June 18, 2018, “Premarket analyst action – healthcare” and the last “Piper Jaffray Remains Bullish on Collegium Pharma (COLL) Ahead of FDA Committee Meeting” with publication date: June 26, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.